Ipsen (I7G) Stock Overview
A biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
I7G Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ipsen S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €131.60 |
| 52 Week High | €139.00 |
| 52 Week Low | €90.20 |
| Beta | 0.20 |
| 1 Month Change | 13.25% |
| 3 Month Change | 11.71% |
| 1 Year Change | 10.03% |
| 3 Year Change | 34.84% |
| 5 Year Change | 85.09% |
| Change since IPO | 498.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| I7G | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.8% | -1.5% | -3.0% |
| 1Y | 10.0% | 14.5% | 10.0% |
Return vs Industry: I7G underperformed the German Pharmaceuticals industry which returned 19.7% over the past year.
Return vs Market: I7G underperformed the German Market which returned 11.4% over the past year.
Price Volatility
| I7G volatility | |
|---|---|
| I7G Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: I7G has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: I7G's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 5,358 | David Loew | www.ipsen.com |
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis.
Ipsen S.A. Fundamentals Summary
| I7G fundamental statistics | |
|---|---|
| Market cap | €10.98b |
| Earnings (TTM) | €447.90m |
| Revenue (TTM) | €3.76b |
Is I7G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I7G income statement (TTM) | |
|---|---|
| Revenue | €3.76b |
| Cost of Revenue | €627.10m |
| Gross Profit | €3.13b |
| Other Expenses | €2.68b |
| Earnings | €447.90m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Feb 12, 2026
| Earnings per share (EPS) | 5.46 |
| Gross Margin | 83.32% |
| Net Profit Margin | 11.91% |
| Debt/Equity Ratio | 19.9% |
How did I7G perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/20 18:43 |
| End of Day Share Price | 2026/01/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ipsen S.A. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Richard Silver | Barclays |
| Charles Pitman | Barclays |